Difference between revisions of "Talquetamab (Talvey)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "clinicaltrials.gov/ct2/show" to "clinicaltrials.gov/study") |
Warner-admin (talk | contribs) m (Text replacement - "/CD3 bispecific" to "-CD3 bispecific") |
||
| (10 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/talquetamab NCI Drug Dictionary]: A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/talquetamab NCI Drug Dictionary]: A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. | ||
| − | == | + | ==Toxicity management== |
| − | + | *[https://www.tec-talrems.com/ Link to REMS program] | |
| − | |||
| + | ==Diseases for which it is established== | ||
| + | *[[Multiple myeloma]] | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *'''2023-08-09:''' Granted accelerated approval for adults with relapsed or refractory [[multiple myeloma]] who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. ''(Based on MonumenTAL-1)'' | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code | + | *'''Code name:''' JNJ-64407564 |
| + | *'''Generic name:''' talquetamab-tgvs | ||
| + | *'''Brand name:''' Talvey | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | + | [[Category:Anti-GPRC5D-CD3 bispecific antibodies]] | |
| − | [[Category:Anti-GPRC5D | ||
| − | |||
| − | [[Category:Multiple myeloma medications | + | [[Category:Multiple myeloma medications]] |
| − | [[Category: | + | [[Category:FDA approved in 2023]] |
| + | [[Category:REMS program]] | ||
Latest revision as of 00:13, 18 October 2023
Mechanism of action
From the NCI Drug Dictionary: A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells.
Toxicity management
Diseases for which it is established
History of changes in FDA indication
- 2023-08-09: Granted accelerated approval for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (Based on MonumenTAL-1)
Also known as
- Code name: JNJ-64407564
- Generic name: talquetamab-tgvs
- Brand name: Talvey